ViraCyte

About ViraCyte

ViraCyte is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe life threatening infections. ViraCyte's current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 1 and Phase 2 clinical trials, with effectiveness rates of greater than 90% in patients who have failed conventional therapy. More information can be found at www.viracyte.com.
YEAR FOUNDED:
2013
LEADERSHIP:
Co-Founder: Juan Vera
Co-Founder: Ann Leen
CEO and President: Brett P. Giroir, MD
Chief Product Development Officer: Juan F. Vera, MD
CSO: Ann M. Leen, PhD
Director, Regulatory Affairs: Bambi J. Grilley,RPh, RAC, CIP, CCRC, CCRP
Managing Director: John R. Wilson
SCIENCE:
Please click here for ViraCyte's science.
PIPELINE:
Please click here for ViraCyte's pipeline.